Display options
Cite
Huang WK, Yang SF, You LN, et al. Transcatheter arterial chemoembolisation (TACE) plus S-1 for the treatment of BCLC stage B hepatocellular carcinoma refractory to TACE. Contemp Oncol (Pozn). 2017;20(6):468-474doi: 10.5114/wo.2016.65607.
Huang, W. K., Yang, S. F., You, L. N., Liu, M., Liu, D. Y., Gu, P., & Fan, X. W. (2016). Transcatheter arterial chemoembolisation (TACE) plus S-1 for the treatment of BCLC stage B hepatocellular carcinoma refractory to TACE. Contemporary oncology (Poznan, Poland), 20(6), 468-474. https://doi.org/10.5114/wo.2016.65607
Huang, Wu-Kui, et al. "Transcatheter arterial chemoembolisation (TACE) plus S-1 for the treatment of BCLC stage B hepatocellular carcinoma refractory to TACE." Contemporary oncology (Poznan, Poland) vol. 20,6 (2016): 468-474. doi: https://doi.org/10.5114/wo.2016.65607
Huang WK, Yang SF, You LN, Liu M, Liu DY, Gu P, Fan XW. Transcatheter arterial chemoembolisation (TACE) plus S-1 for the treatment of BCLC stage B hepatocellular carcinoma refractory to TACE. Contemp Oncol (Pozn). 2016;20(6):468-474. doi: 10.5114/wo.2016.65607. Epub 2017 Jan 12. PMID: 28239285; PMCID: PMC5320460.
Copy Download .nbib Format: NLM
Share it on

Contemp Oncol (Pozn). 2016;20(6):468-474. doi: 10.5114/wo.2016.65607. Epub 2017 Jan 12.

Transcatheter arterial chemoembolisation (TACE) plus S-1 for the treatment of BCLC stage B hepatocellular carcinoma refractory to TACE.

Contemporary oncology (Poznan, Poland)

Wu-Kui Huang, Shu-Fa Yang, Li-Na You, Mo Liu, Deng-Yao Liu, Peng Gu, Xi-Wen Fan

Affiliations

  1. Department of Intervention Radiology, the Affiliated Tumour Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China; These authors contributed equally to this work.
  2. Department of Traditional Chinese Medicine, the Fifth Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China; These authors contributed equally to this work.
  3. Department of Intervention Radiology, the Affiliated Tumour Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China.

PMID: 28239285 PMCID: PMC5320460 DOI: 10.5114/wo.2016.65607

Abstract

AIM OF THE STUDY: To assess the efficacy and safety of transcatheter arterial chemoembolization (TACE) plus S-1 for the treatment of Barcelona Clinic Liver Cancer (BCLC) Stage B HCC refractory to TACE.

MATERIAL AND METHODS: 26 patients meeting the eligibility criteria were enrolled. TACE was given on day 1, and S-1 on days 2-15. Tumor assessment was performed one month later according to mRECIST. The primary endpoints were TTP and OS.

RESULTS: Twenty-six patients received 176 TACE interventions in all. Fifteen patients of TACE plus S-1 received a total of 55 cycles of treatment of S-1, with a median of 4 cycles (range, 2-6). The total dose of S-1 was 6165 mg per day, while average was 120 mg (range, 100-125 mg) for 15 patients of TACE plus S-1. Median TTP and OS of TACE plus S-1 were 6 months (95% CI: 4.7-7.3) and 18 months (95% CI: 15.3-24.7), respectively, while TACE monotherapy was 4 months (95% CI: 2.4-5.6) and 13 months (95% CI: 9.8-16.2), respectively, and significant differences were detected. Though there were higher DCRs in patients of TACE plus S-1, no significant differences were detected. A total of 612 adverse events occurred during the course of the treatment, 367 in TACE plus S-1 and 245 in TACE mono-therapy. There were significant differences to anorexia and nausea, but they were tolerable.

CONCLUSIONS: TACE plus S-1 in the present analysis was tolerable and associated with an interesting TTP and OS. TACE plus S-1 may be used as a new treatment method to BCLC Stage B HCC refractory to TACE.

Keywords: S-1; hepatocellular carcinoma; transcatheter arterial chemoembolisation

References

  1. World J Gastroenterol. 2014 Jan 7;20(1):235-41 - PubMed
  2. Hepatology. 2011 Mar;53(3):1020-2 - PubMed
  3. Dig Dis. 2011;29(3):339-64 - PubMed
  4. Pharmazie. 2014 Oct;69(10):759-63 - PubMed
  5. Eur J Cancer. 2011 Sep;47(14):2117-27 - PubMed
  6. CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 - PubMed
  7. J Clin Oncol. 2009 Mar 20;27(9):1485-91 - PubMed
  8. Oncol Rep. 2008 May;19(5):1355-61 - PubMed
  9. N Engl J Med. 2008 Jul 24;359(4):378-90 - PubMed
  10. J Hepatol. 2001 Sep;35(3):421-30 - PubMed
  11. Liver Int. 2015 Jan;35(1):223-31 - PubMed
  12. Contemp Oncol (Pozn). 2016;20(1):20-7 - PubMed
  13. J Gastroenterol. 2014 May;49(5):932-40 - PubMed
  14. Lancet Oncol. 2009 Jan;10(1):25-34 - PubMed
  15. J Hepatol. 2006 Oct;45(4):529-38 - PubMed
  16. Cancer Sci. 2010 Dec;101(12):2606-11 - PubMed
  17. J Hepatol. 2012 Jun;56(6):1330-5 - PubMed
  18. Oncol Rep. 2014 Jan;31(1):65-72 - PubMed
  19. Cardiovasc Intervent Radiol. 2007 Jan-Feb;30(1):6-25 - PubMed
  20. Jpn J Clin Oncol. 2009 Jan;39(1):2-15 - PubMed
  21. Hepatology. 2003 Feb;37(2):429-42 - PubMed
  22. Int J Cancer. 2015 Mar 15;136(6):1458-67 - PubMed
  23. Lancet. 2002 May 18;359(9319):1734-9 - PubMed
  24. Hepatology. 2002 May;35(5):1164-71 - PubMed
  25. Hepatology. 2005 Nov;42(5):1208-36 - PubMed
  26. J Hepatol. 2012 Apr;56(4):908-43 - PubMed
  27. Anticancer Res. 2010 Dec;30(12):5245-50 - PubMed

Publication Types